2-3%: From the study that leads the approval of Revlimid (lenalidomide) -the data showed that there were 9/346 (2.6%) patients in the Revlimid (lenalidomide) group who developed grade 3 atrial fibrillation compared to 2/345 (0.6%) patient who developed grade 3 atrial fibrilation in the placebo group.
Answered 9/28/2016
5.3k views
6 doctors weighed in across 2 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question